about
Current issues in oncology drug development, with a focus on Phase II trialsRandomized phase II clinical trials.Randomized phase II trials: time for a new era in clinical trial designGefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study.Screened selection design for randomised phase II oncology trials: an example in chronic lymphocytic leukaemiaGefitinib in Combination with Weekly Docetaxel in Patients with Metastatic Breast Cancer Caused Unexpected Toxicity: Results from a Randomized Phase II Clinical Trial.NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.SMART Design Issues and the Consideration of Opposing Outcomes: Discussion of "Evaluation of Viable Dynamic Treatment Regimes in a Sequentially Randomized Trial of Advanced Prostate Cancer" by by Wang, Rotnitzky, Lin, Millikan, and Thall.Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder CancerClinical trials of novel and targeted therapies: endpoints, trial design, and analysis.Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trialCyclosporine C2 monitoring for the treatment of frequently relapsing nephrotic syndrome in children: a multicenter randomized phase II trialStatistical methods for down-selection of treatment regimens based on multiple endpoints, with application to HIV vaccine trials.Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial.Between-arm comparisons in randomized Phase II trialsDesigns for randomized phase II clinical trials with two treatment arms.A Bayesian pick-the-winner design in a randomized phase II clinical trial.Optimal cost-effective designs of Phase II proof of concept trials and associated go-no go decisions.
P2860
Q33433456-1981A5F4-356C-4A46-8A60-6B2445AB5D48Q33624082-25C0CAE3-735A-486E-8C02-6718D01A50E1Q34137050-4C3EFC12-9298-47DC-A115-471C730E2C43Q34781067-B2EC89C9-31E6-4B04-AC88-54815528ED92Q34790388-A4ED707F-00FD-4017-A7EC-1F49F7FC7785Q35990886-A82A23E6-8604-40EB-98C4-62FA08210DFCQ36507559-9FDAA307-93C4-4ACF-8D94-5701153FDD67Q36713954-20EEE949-563D-4104-84F2-475471FC97D5Q37053820-8A2D631D-603A-4B8F-9722-8B7EB6BCD196Q37196395-05BC0BAE-A921-4FD9-8ED9-FC24601F5904Q37267608-77E5A993-4E32-4A22-A6C6-97FCCB403BB4Q37553134-DE8448CD-3307-46C3-97A0-049EDDBCE395Q40533695-8D510362-B669-4400-809B-F883FA57EF3DQ41044036-BD035E88-C5D4-4177-B169-ABC3770030F3Q42012850-0108FFCE-C183-40DD-AB28-A4194F22FF7EQ46031432-22AD3A39-7C88-4808-B923-8EDE4D7F6B4AQ47095307-2364F3CB-A56B-47F0-9F45-C71D485877FBQ54220825-C82975DC-2C7B-4A8B-B33B-D768461CB672
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
A flexible design for multiple armed screening trials.
@ast
A flexible design for multiple armed screening trials.
@en
type
label
A flexible design for multiple armed screening trials.
@ast
A flexible design for multiple armed screening trials.
@en
prefLabel
A flexible design for multiple armed screening trials.
@ast
A flexible design for multiple armed screening trials.
@en
P2860
P356
P1476
A flexible design for multiple armed screening trials.
@en
P2093
Goldberg RM
Sargent DJ
P2860
P304
P356
10.1002/SIM.704
P407
P577
2001-04-01T00:00:00Z